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Background: Porcine endogenous retroviruses (PERVs) pose a potential risk for xenotransplantation 
using pig cells, tissues or organs. A special threat comes from viruses generated 
by recombination between human-tropic PERV-A and ecotropic PERV-C. 
Serial passages of a recombinant PERV-A/C on human 293 cells resulted in increased infectious titers 
and a multimerization of transcription factor binding sites in the viral long terminal repeat (LTR). 
In contrast to the LTR, the sequence of the env gene did not change, indicating that the LTR 
represents the determinant of high infectivity. 
 
Material/Methods: The virus was further propagated on human cells and characterized by different 
methods (titration, sequencing, infection experiments, electron microscopy). 
 
Results: Further propagation on human 293 cells resulted in deletions and mutations in the LTR.  
In contrast to low-titer viruses, the high-titer virus was infectious for cells from non-human primates 
including chimpanzees. Scanning electron microscopy revealed clustering of budding virions at the cell 
surface of infected human cells and transmission electron microscopy indicated that the virus infects 
them via receptor-mediated endocytosis. 
 
Conclusions: After propagation of PERV on human cells without selection pressure, viruses 
with different LTR were generated. High titer PERV was shown to infect cells from non-human 
primates. The experiments performed here simulate the situation in vivo and give an extended 





Xenotransplantation may develop into a medical technology able to save life or improve its quality. 
Porcine endogenous retroviruses (PERVs) are considered to be the main microbiological risk if 
pig cells tissues or organs are to be transplanted as they (i) are integrated in numerous copies in 
the genome of all pig strains [1–3], (ii) are produced by normal pig cells [4–7], (iii) infect human 
cell in vitro [2,8,9] and (iv) have immunosuppressive properties[10,11]. Three subclasses of 
infectious PERV have been described, polytropic, human-tropic PERV-A and PERV-B as well as 
ecotropic PERV-C [12]. Infection studies with PERV showed a productive infection of primary cells of 
different species including non-human primates [13].  
However, evidence for PERV transmission was neither seen in patients who had received porcine 
xenotransplants nor in butchers frequently exposed to pig tissues [14–17]. Similarly, rats, 
rhesus macaques, pig tailed macaques and baboons inoculated with high doses of PERV and 
given strong daily immunosuppressive treatment failed to exhibit evidence of infection [18–22]. 
In guinea pigs a transient infection was observed, however with a low virus load unable to induce a 
specific antiviral immune response [23]. 
Recently, recombinant PERV-A/C able to infect human cells were described which de novo integrated 
into the genome of spleen cells of miniature pigs and melanoma-bearing pigs, but they were not 
found in the germ line of these animals [24–28]. 
  
Serial cell-free passaging of PERV-A/C on human cells, simulating the situation after 
xenotransplantation, resulted in an increase in the titer of the virus [29,30]. This increase was 
associated with genetic changes in the viral LTR, in particular with a multimerization 
of NF-Y transcription factor binding sites in the LTR. Similar changes in the LTR were 
observed when PERV-A was passaged [29,31]. On the other hand, comparison of highly replication 
competent PERV-A/C with the paternal PERV-A identified mutations in the env gene that may be 
responsible for higher titers [32]. 
To characterize the possible evolution of PERVs in xenotransplant recipients, high-titer PERVA/ 
C with a longer LTR were obtained after rapid passages on human cells and then cultured for a 
long time without passaging. Deletions and mutations were observed after long term culture. 
In addition, infection and release of high-titer PERV-A/C were studied by electron 
microscopy,determinants of high infectivity were screened for and infectivity for non-human primate 
cells was studied. 
 
 
Material and Methods 
 
 
Viruses, virus passages and long-term cultures 
 
PERV/5° was obtained from PERV-NIH, 3
rd
 passage (PERV-NIH/3°, kindly provided by C. 
Wilson, FDA, Washington, DC, USA) by cellfree passaging on human 293 cells in the presence 
of 8 μg/ml polybrene (Sigma, Deisenhofen, Germany) [29]. PERV-NIH/3° has been derived 
from 293 cells infected with PERV released from stimulated pig lymphocytes after two consecutive 
passages on 293 cells [7,33]. PERV-NIH/3° has been shown to represent a recombination 






Virus-containing supernatant produced by a confluent PERV-producing cell culture (1×107 293 
cells) was taken three days after the last medium change. Cells were removed by centrifugation 
and sterile filtration (0.45 μm) and the supernatant was serially diluted before transfer to 
96-well plates containing uninfected 293 cells (3×104/well) and incubated at 37°C with 5% 
CO2 and 98% humidity. Titers were determined measuring provirus integration by PCR or by 
real time PCR. 
 
 
PCR and cloning of PERV LTRs 
 
For direct amplification of a PERV 5’ LTR sequence the primers PK34 (nt3 to 26) and PK26 
(nt1134 to 1111) [31] (Table 1) were used. 
Amplification was carried out using standard PCR conditions in a Biozym cycler (Biozym Diagnostic, 
Oldendorf, Germany): one initial cycle of 10 minutes denaturation at 95°C, 35 cycles of 1 minute 
denaturation at 95°C, 1 minute annealing at 58°C, 1 minute elongation at 72°C, and one final cycle 
of 7 minutes elongation at 72°C. The amplicons were cloned into a pCR2.1-TOPO vector 
(Invitrogen). In addition, the primers LTR up and LTR down were used (Table 1). 
 
 
PCR and cloning of env 
 
DNA from PERV producing cells was extracted using the QIAamp DNA MiniKit (Qiagen).  
The env gene was amplified using primers Env up and Env down (Table 1). The PCR product was 
purified, digested with the restriction enzymes SacI and PstI and cloned into the vector pQE30 
(Qiagen). The sequence of the insert was determined by DNA sequence analysis (Medigenomix). 
 
  
Transmission electron microscopy (TEM) 
 
PERV/5° producing 293 cells were fixed with 2.5% glutaraldehyde in HEPES, pH 7.2, for 30 
min or several days and investigated as described [34]. The samples were washed with HEPES and 
fixed with 1% osmium tetraoxide for 1 h. To increase the contrast, specimens were treated with 
1% tannic acid for 1 h after osmification and block embedded by mixing equal amounts of 
cell sediment and low melting agarose (3% in PBS) in the tip of Pasteur pipette. After gelling, 
the agarose was cut into blocks 1 mm in length, stained for 1 h with 1% uranyl acetate, dehydrated 
in a graduated ethanol series and embedded in Epon.  
Thin sections were cut on a Leica- Ultracut ultramicrotome, mounted on naked 300 mesh copper grids, 
and post-stained with lead citrate. 
Sections were stabilised with a thin layer of carbon evaporation and evaluated using a Zeiss EM 902 
at 80 kV. 
 
 
Scanning electron microscopy (SEM) 
 
PERV/5° producing 293 cells were grown on cover-glasses or after resuspension adsorbed to 1% 
alcian blue-treated cover-glasses for 20 min at room temperature and fixed with 2.5% glutaraldehyde 
in PBS for 30 min followed by 1% osmium tetraoxide for 1 h. Specimens were dehydrated in a 
graduated ethanol series, critical-point dried in carbon dioxide, and mounted on SEM specimen 
stubs. Samples were sputter coated with an 8 nm layer of gold and evaluated in a LEO 1530-SEM 
at 5 kV.  
For cryo scanning electron microscopy the cover-glasses with PERV/5° producing cells 
were immediately cryofixed in liquid propane after glutaraldehyde fixation, mounted on the specimen 
holder of a BAL TEC cryopreparation unit MED 020 and freeze-dried for 3 h.  
Specimens were than sputter coated with platinum with a thickness of up to 2–3 nm, transferred with 
the BAL TEC transfer-unit VCT into the same scanning electron microscope and evaluated under cryo 
conditions at –100°C and 1–3 kV. 
 
 
Cloning and sequencing of PERV-A/C molecular clones 
 
Proviral DNA was isolated from cells freshly infected with PERV/5° and cloned into the expression 
vector pcDNA3.1(+) (Invitrogen, Carlsbad, USA). The neo resistance gene was removed from 
the vector using Not I and BstZ17 I. First, amplification was performed using a primer in the 5’ R 
region of the LTR (PERV-LTR-R Spe I) and in the env region (PERV-gp70-blunt down) (Table 1), 
the amplicon was digested at the single Kpn I restriction site. pcDNA3.1(+) was also digested 
using Kpn I. Second, an amplification was performed using the primers PERV-3’-LTR-Kpn I 
down and PERV-gp70-mid-SacI up, digested again with Kpn I and both were ligated to obtain a 
fulllength clone. For the first clone the CMV promotor was used, for the second both LTRs were 
amplified and cloned into the pCR-XL-TOPO vector.  
Sequencing was performed using different primer pairs. 
 
 
Infection of non-human primate cells 
 
Rhesus LLCMK2 kidney cells (ATCC) and EBV transformed lymphoblastoid cells from a male 
chimpanzee (ECACC) were incubated in the presence or absence of 8 μg/ml polybrene.  
To confirm and characterize infection, DNA and RNA were isolated at different time points and 
analyzed for provirus integration using primers specific for pol, env-A [9] and allowing to discriminate 






Influence of passaging and long-term culture on recombinant PERV-A/C 
 
Previously we had shown that rapid passaging of PERV/NIH/3°, a recombinant between 
PERV-A and -C [7,30] on human 293 cells increased the infectious titer of the viruses from 
5.3×101 (PERV/NIH/3°, third passage) to 8.3×103 (PERV/5°, fifth passage) and the length of the 
LTR increased due to a multimerization of 37 bp repeats containing transcription factor NF-Y binding 
sites [29].  
Both viruses contained the receptor- binding domain of PERV-A (and therefore infect 
human cells) and the LTR of PERV-C, which increased in length during culture. The longest 
LTR contained 5 repeats (Figure 1A). However, when PERV/5° was cultured for months on human 
293 cells without selection pressure, the length of the LTR decreased again (Figure 1B, Figure 2).  
This virus was called long-term passaged virus (PERV/LT).  
Due to a deletion (aa 415–452) and one point mutation in position 508, PERV/LT has lost two NF-Y 
binding sites (ATTGG) and due to a mutation in position 478 it lost one CCAAT enhancer-binding 
protein (CEBP) binding site (GAAA). These data may reflect genetic changes in PERVs after infecting 
humans in vivo. 
 
 
Sequencing the cloned virus 
 
In order to clone a whole recombinant PERV-A/C, DNA and RNA from cells infected with PERV/5° 
and the cloning strategies described in Materials and methods were used.  
Two full-length clones were prepared, one using a CMV promotor, another amplifying both LTR. The 
whole genome of the last clone was sequenced using different primer pairs (see AY953542).  
One clone obtained carried an LTR corresponding to PERV/4° containing two NF-Y binding sites.  
This clone was later upgraded with an LTR from PERV/5° containing five repeats. These sequencing 
data confirm results shown in Figure 2B, indicating that after long term culture of cells previously 
infected 
with PERV/5° proviruses with different LTRs were found expressed, mainly PERV/5° and PERV/LT, 
but obviously also a few PERV/4°. 
 
 
Search for high-titer determinants 
 
In order to identify determinants responsible for the enhanced titer of the human cell adapted virus, the 
sequences of the env genes (coding for the surface envelope protein gp70 and the transmembrane 
envelope protein p15E) from PERV-NIH/3°, PERV/5° and PERV/LT were compared.  
No changes in the sequence of the receptor-binding site were found. Only a difference in two amino 
acids (G231R and E415G) had been observed when comparing the env genes of PERV/5° and 
PERV/LT.  
Although a substitution at position I140V and another in the proline rich region were recently identified 
as two determinants of high infectivity of a high titer A/Crecombinant virus (PERV-A14/220), which is 
500 fold more infectious than the parental PERV-A [32], here the I140V substitution was already 
found in PERV/NIH/3°, and therefore it could not be the reason for higher titers after passaging. 
No alterations were observed in the proline rich region. The results indicate that the changes 
in the LTR are likely the determinants of high titer replication. 
 
 
Morphological characterization of PERVs serially passaged on human cells 
 
Since release of PERV particles from porcine PK-15 cells as well as from 293 cells infected 
with PERV-A is very low [10,19], the situation in the case of 293 cells infected with PERV/5° was 
analyzed.  
Although no differences in the morphology, in the budding and infection process 
of PERV/5° compared with PERV derived from PK-15 cells or produced on human 293 cells were 
observed by transmission electron microscopy, a very high number of particles was observed 
(Figure 3).  
These data were confirmed by scanning electron microscopy showing massive budding 
  
of PERV/5° particles from human 293 cells (Figure 4A). By high quality cryo scanning electron 
microscopy budding in distinct areas of the cell surface was demonstrated (Figure 4B). It is 
likely that, as in the case of other retroviruses including HIV-1, the areas of the cell membrane 
where budding occurs are characterized by a particular lipid content, representing the so-called 
‘lipid rafts’ [35,36].  
These data demonstrate that massive budding takes place on the surface of human 
293 cells infected with PERV/5°. The presence of “coated pits” during infection (Figure 3, 
infection, b) indicate that PERV/5° infects human cells via receptor-mediated endocytosis. 
 
 
Generation of a real time RT-PCR measuring full-length and spliced mRNA 
 
The presence of spliced env mRNA is a prerequisite for the translation of the Env protein and 
particle release. The full-length mRNA encodes for Gag and Pol, the spliced mRNA for Env.  
To detect spliced mRNA in cells expressing PERV, a RT-PCR was developed.  
To discriminate between full-length mRNA and spliced RNA specific primers were placed in front or 
behind the 
splice donor as well as behind the splice acceptor (Figure 5). Utilization of this primer combination 
allowed detecting three different amplicons: Two amplicons (380 and 480 bp) corresponding 
to differently spliced mRNA detected in PK-15 cells releasing PERV-A and PERV-B, and another 
of 470 bp corresponding to PERV/5°.  
This method allows detection of spliced mRNA and an estimation of the probability of protein 
expression and particle release. 
 
 
Infection of non-human primate cells 
 
PERV/5° has been shown to infect cells from numerous 
species in vitro including primary PBMCs from rhesus monkeys and baboons [18,22]. To 
analyze, whether PERV/5° is able to infect rhesus and chimpanzee cell lines, rhesus LLCMK2 
kidney cells and EBV transformed lymphoblastoid cells from chimpanzees (EB176 cells) were 
incubated with cell-free supernatant containing PERV/5°. Infection was detected in the absence or 
presence of polybrene one, two or three weeks after infection (Figure 6). To study virus expression 
in a long-term culture, rhesus LLCMK2 kidney cells and EBV transformed chimpanzee lymphoblastoid 
cells (EB176 cells) were infected with PERV/5° and cultured over weeks (Figure 7). 
Full length mRNA was detected immediately, whereas spliced mRNA was detected only after 
one week. As mentioned above, the presence of spliced env mRNA is a prerequisite for the production 
of Env protein and release of virus particles. 
Although low RT activity was observed in the supernatant, indicating release of virus particles, 






The high-titer PERV-A/C (PERV/5°) was originally obtained by cell-free passaging of a 
PERV-A/C on human cells in short time intervals (simulating a high selection pressure) and it 
is characterized by an increase in the number of NF-Y transcription factor binding sites (Figure 1). 
When PERV/5o was cultured without passaging (absence of selection pressure), viruses with a 
lower number of NF-Y binding sites, with mutations and deletions accumulated.  
This experiment simulates the possible evolution of PERV after infection of a human xenotransplant 
recipient. 
This experiment also demonstrated that PERV-A/C recombinant viruses might represent 
a new risk for xenotransplantation due to the high replication titers [10,37]. Analyzing the 
reason for the high titers of PERV-A/C recombinants in comparison with parental PERV-A, 
an isoleucine to valine substitution at position 140 in the receptor-binding site and changes in 
the proline rich region had been reported in PERV/5° [32].  
In addition, an enhanced reverse transcriptase (RT) activity of PERV-A/C viruses when compared with 
the RT activity of PERV-A was described [38]. Since in our case the I140V 
substitution had been detected already in an early passage of PERV/5°, and no changes in 
the proline rich region were found, all changes leading to higher titers have to be attributed 
  
to the alterations in the LTR. It is interesting to note, that in the genome of German landrace 
pigs and Yucatan micropigs, proviruses carrying PERV-C LTRs with five 37 bp repeats were not 
found (unpublished data). 
To avoid the generation of high-titer PERV-A/C recombinants, it is recommended not to use pig 
strains carrying ecotropic PERV-C for breeding [39].  
Whereas PERV-A and PERV-B are present in all pig strains, PERV-C is missing in some of them 
[12]. However, a recent screening for PERV-C-free animals in colonies of non-transgenic (including 
18 wild boars) and multitransgenic animals generated to prevent hyperacute rejection, demonstrated 
that only 5 of 181 animals were PERV-C negative, indicating that this virus is widely distributed [40]. 
The results presented here are important for the evaluation of a non-human primate model for 
analyzing PERV transmission. Non-human primate cells carry the receptor for PERV [41] and 
can be infected in vitro [19,22,42,43], however no transmission was observed in vivo [22,44,45]. 
Not only cell lines from non-human primates such as baboon and rhesus monkey have been infected 
in vitro, even primary cells from these animals were infected using high-titer PERV [19]. A 
productive infection of cells from baboons and rhesus monkeys was demonstrated by increasing 
reverse transcriptase activity over time in the supernatant and viral genomic RNA in the pelleted 
virus.  
Cells from pig-tailed monkeys could not be infected productively, only integrated proviral 
DNA, but no release of virus particles was observed [19], whereas Ritzhaupt et al. [42] showed 
that cell lines from African green monkeys, rhesus macaques, and baboons were infected with 
PERV as measured by viral DNA integration and RNA expression using PCR and RT-PCR assays, 
respectively. Virions released from these infected cells infected productively human 293 cells, 
but not cells from non-human primates.  
This indicatesthat a productive infection, but no replication took place. The low replication rate of 
PERV in primate cells including most human cells may be explained by inhibition of virus replication 
by intracellular restriction factor such as TRIM5a and members of the APOBEC family 
[46,47].  
However, it has been shown that cellular restriction factors can be neutralized by higher 
virus doses, enabling to achieve productive infection at high virus titers and that some PERVs 
are insensitive to mammalian TRIM5a [38].  
In addition, there is evidence that the function of the non-human primate PERV-receptor is not optimal 
[48]. Based on these results there is an ongoing discussion whether the appropriateness of 
nonhuman primates as suitable animal models needs re-evaluation.  
However, as shown by different laboratories, it was also difficult to infect productively most human 
primary cells and cell lines with exception of 293 kidney cells (which were transformed by adenovirus 5 
and do not express APOBEC). 
Of great interest is the mechanism of PERV infection shown here by electron microscopy. We 
demonstrate that the virus infected human cells by receptor-mediated endocytosis (Figure 3).  
Only recently a similar mechanism has been described for HIV-1 [49]. The knowledge of this 
mechanism has important implications for the development of vaccines, especially for the generation 






Although not yet described, multimerization of transcription factor binding sites may also occur 
in vivo, in a virus released from the xenotransplant and adapting to human cells during experimental 
or clinical xenotransplantation.  
However, in vivo transmission of PERV has been observed neither in first clinical xenotransplantations 
nor in experimental xenotransplantations with rats and monkeys using organs, cells or cell-free 
PERVs [for review see 33]. In monkeys undergoing triple immunosuppressive therapy to simulate 
the conditions during xenotransplantation no in vivo infection with PERV was observed even when 
high doses of high-titer PERV-A/C were inoculated [22].  
The extensive genetic, biochemical and morphological characterization of PERVs being 
used in several in vitro and in vivo infection experiments is crucial for the safety evaluation of 
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Table 1. Primers and probes used. 
 
Primers/probes    Sequence 
 
PK34      AAAGGATGAAAATGCAACCTAACC 
PK26      ACGCACAAGACAAAGACACACGAA 
LTR up     TCTTGGTGACAACATGTCTC 
LTR down     AGTGTGGAGTCGGGACAGCT 
Env up     TTATGAGCTCATGCATCCCACGTTAAGCC 
Env down     CCCAACTGCAGTCTTTTTGGCCGATTATATCT 
PERV-LTR-R Spe I   AATTACTAGTGCGTGGTGTACGACTGTGGG 
PERV-gp70-blunt down   TCTTTTTGGCCGATTATATCT 
PERV-3’-LTR-Kpn I down   TCTCGGTACCGATGCAAACAGCAAGAGGAT 
PERV-gp70-mid-SacI up   AACTGAGCTCGATGGGAATTGGAAATGGCC 
Pol up     TTGACTTGGGAGTGGGACGGGTAAC 
Pol down     GAGGGTCACCTGAGGGTGTTGGAT 
Env A up     TGGAAAGATTGGCAACAGCG 
Env A down     AGTGATGTTAGGCTCAGTGG 
P1 (In front of SD*)    TGCTGTTTGCATCAAGACCGC 
P2 (Behind SD)    ACAGACACTCAGAACAGAGAC 
P3 (Behind SA**)    ATGGAGGCGAAGCTTAAGGGGA 
 
* SD – splice donor; **SA – splice acceptor. 
  
Figure 1. (A) Schematic presentation of the repeat sequences in the LTR of PERV/5°. Dark grey 
indicates a single 21bp domain, white and light grey a 37bp repeat with the sequences shown. (B) 
Sequences of PERV/3°, PERV/5° and PERV/LT, the domains as shown in A are indicated above the 
sequence. Factor NF-Y bindings sites are underlined (ATTGG), putative binding sites for CEBP are in 
bold, the TATA box is framed. 
  
Figure 2. Analysis of PCR amplification using (A) env specifc and (B) LTR specific primers.  
In A amplification was performed using primers located in the receptor binding 
site of PERV-A, 1 – water, 2 – uninfected 293, 3 – PERV/3°, 4 – PERV/5°, 5 – PERV/LT, 6 – env 
plasmid.  
In B amplification was performed using LTR specific primers, 1 – uninfected 293 cells, 2–293 cells 
infected with PERV/3°, 3–293 cells infected with PERV/4°, 4–293 cells infected with PERV/5°, 5, 6–
































Figure 4. (A) Release of PERV/5° particles on the surface of human 
293 cells (scanning electron microscopy) and (B) (cryo scanning electron microscopy), 






Figure 5. Development of a PCR assay detecting full-length and spliced mRNA of PERV using 
selected primers in the LTR (P1, in front of the splice donor SD, P2, behind the splice 
donor SD) and in the env region behind the splice acceptor SA (P3).  
Full-length, spliced mRNA, β-actin and β-actin without reverse transcriptase indicating absence 
of DNA contamination were studied in 293 cells infected with PERV/5° (PERV-A/C), in pig kidney cells 









Figure 6. Infection of rhesus kidney cells LLCMK2 (A) and lymphoid 
chimpanzee cells (EB176) (B) with PERV/5° (PERVA/ C), (–) indicates absence, (+) presence of 





Figure 7. Long-term culture of PERV/5° (PERV-A/C) on rhesus kidney cells LLCMK2 (A) and 
lymphoid chimpanzee cells (EB176) (B). Using specific primers, full-length mRNA 
and spliced RNA as well as β-actin with and without reverse transcriptase (-RT) were studied in these 
cells over 7 to 8 weeks. 
 
 
 
